Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.41 |
| ▸ | TSPO | P30536 | 4/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053395 | 0.91 | GPBAR1 (0.40) | SGMS2MAPTGPBAR1TSPOALB | |
| SCHEMBL3064290 | 0.90 | TSPO (0.48) | MAPTGPBAR1TSPOALBNOS3 | |
| SCHEMBL3043781 | 0.89 | KDM4C (0.41) | MAPTGPBAR1TSPOALBTACR1 | |
| SCHEMBL3058487 | 0.86 | GPBAR1 (0.46) | MAPTGPBAR1TACR1NOS3NOS1 | |
| SCHEMBL3061240 | 0.84 | NOS3 (0.47) | SGMS2MAPTGPBAR1TACR1NOS3 | |
| SCHEMBL3057509 | 0.80 | TRPM8 (0.45) | MAPTGPBAR1TACR1 | |
| SCHEMBL3043589 | 0.80 | NOS3 (0.49) | GPBAR1TSPOALBTACR1NOS3 | |
| SCHEMBL3054331 | 0.76 | NOS3 (0.47) | MAPTGPBAR1TSPONOS3NOS1 | |
| SCHEMBL3058597 | 0.75 | TACR1 (0.43) | MAPTGPBAR1TACR1 | |
| SCHEMBL3058702 | 0.74 | TSPO (0.51) | SGMS2GPBAR1TSPOALBNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| CN-101405268-A | Amide derivatives and their use for the treatment of protein-related diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | SGMS2 1822/4885MAPT 2871/4885GPBAR1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.